Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy
MedComm · 2026-05 · 7 (5)
DOI: 10.1002/mco2.70742 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 21.04.2026. Verfasst von Wanlin He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center For Immuno-Oncology Nuffield Department of Medicine University of Oxford Oxford UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 409 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine.
Abstract (Originalsprache)
Immunotherapies have transformed the treatment of cancers and infectious diseases by harnessing the precision and adaptability of the immune system. Central to these advances is the major histocompatibility complex (MHC) system, with classical MHC‐I molecules well documented for their role in immune surveillance. MHC‐dependent therapies, including immune checkpoint blockade (ICB), T cell receptor (TCR)‐engineered therapies, and cancer vaccines, have shown substantial clinical promise. However, their broader efficacy is hindered by the extreme polymorphism of classical MHC‐I molecules, susceptibility to immune evasion, and frequent downregulation in many disease settings. In contrast, nonclassical MHC‐I molecules, including HLA‐E, HLA‐F, HLA‐G, CD1, and MR1, offer alternative therapeutic opportunities. Shaped by strong evolutionary conservation, these molecules exhibit limited polymorphism, specialized antigen repertoires, distinct trafficking behaviors, and the capability to engage both innate and adaptive immune cells. In this review, we synthesize current knowledge of the structural biology, antigen presentation pathways, receptor interactions, and immunoregulatory functions of nonclassical MHC‐I molecules. We further highlight emerging therapeutic strategies, including immune checkpoint modulation, cargo‐based ligands, conformation‐specific biologics, vaccines, and cellular therapies, while critically evaluating translational challenges. By linking specialized structural and functional features to therapeutic design, this review provides a unified framework for exploiting nonclassical MHC‐I molecules as next‐generation targets in immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center For Immuno-Oncology Nuffield Department of Medicine University of Oxford Oxford UK.
- State Key Laboratory of Oral Diseases & National Center For Stomatology and National Clinical Research Center For Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu China.
- Chinese Academy of Medical Sciences Oxford Institute Nuffield Department of Medicine University of Oxford Oxford UK.
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
Zitieren
APA
He, W., & McMichael, A. J. (2026). Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy. MedComm, 7(5). https://doi.org/10.1002/mco2.70742
Vancouver
He W, McMichael AJ. Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy. MedComm. 2026;7(5). doi:10.1002/mco2.70742
BibTeX
@article{He2026,
author = {He, Wanlin and McMichael, Andrew J},
title = {Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy},
journal = {MedComm},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/mco2.70742}
}
EUVIMED